Anticoagulation monitoring during vascular surgery: Accuracy of the Hemochron® low range activated clotting time (ACT-LR)

British Journal of Anaesthesia

Volumn 97, Issue 4, 2006, Pages 453-459

  Tremey, B ^a   Szekely, B ^a   Schlumberger, S ^a   Francois D ^a   Liu, N ^a   Sievert, K ^a   Fischler, M ^a  

^a FOCH HOSPITAL   (France)

Author keywords

Blood, anticoagulants, heparin; Blood, coagulation; Blood, whole blood coagulation time; Surgery, vascular

Indexed keywords

AMINOCAPROIC ACID; APROTININ; ATRACURIUM; BLOOD CLOTTING FACTOR 10A; CETIRIZINE; HEPARIN; ISOFLURANE; PROPOFOL; PROTAMINE; SUFENTANIL;

ACCURACY; ADULT; AGED; ANESTHESIA INDUCTION; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HUMAN; INTERMETHOD COMPARISON; KAPPA STATISTICS; MAINTENANCE DRUG DOSE; MALE; MEASUREMENT; PATIENT MONITORING; PREMEDICATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; VASCULAR SURGERY;

EID: 33748848671     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/ael194     Document Type: Article

References (31)

1. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 609S-26S
2. Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46-54
3. de Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-8
4. McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. J Pharmacokinet Biopharm 1979; 7: 331-54
5. Mabry CD, Thompson BW, Read RC, Campbell GS. Activated clotting time monitoring of intraoperative heparinization: Our experience and comparison of two techniques. Surgery 1981; 90: 889-95
6. Poisik A, Heyer EJ, Solomon RA, et al. Safety and efficacy of fixed-dose heparin in carotid endarterectomy. Neurosurgery 1999; 45: 434-41
7. Martin P, Greenstein D, Gupta NK, Walker DR, Kester RC. Systemic heparinization during peripheral vascular surgery: Thromboelastographic, activated coagulation time, and heparin titration monitoring. J Cardiothorac Vasc Anesth 1994; 8: 150-2
8. Szalados JE, Ouriel K, Shapiro JR. Use of the activated coagulation time and heparin dose-response curve for the determination of protamine dosage in vascular surgery. J Cardiothorac Vasc Anesth 1994; 8: 515-8
9. Castellan L, Causin F, Danieli D, Perini S. Carotid stenting with filter protection. Correlation of ACT values with angiographic and histopathologic findings. J Neuroradiol 2003; 30: 103-8
10. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-40
11. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques. Anesthesiology 1999; 91: 1122-51
12. Rath B, Bennett DH. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J 1990; 63: 18-21
13. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961-6
14. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69: 674-84
15. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978; 26: 231-40
16. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193: 105-11
17. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-82
18. Paniccia R, Fedi S, Carbonetto F, et al. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test. Anesthesiology 2003; 99: 54-9
19. Ambrose TM, Parvin CA, Mendeloff E, Luchtman-Jones L. Evaluation of the TAS analyzer and the low-range heparin management test in patients undergoing extracorporeal membrane oxygenation. Clin Chem 2001; 47: 858-66
20. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S
21. Cox DJ, Clarke WL, Gonder-Frederick L, et al. Accuracy of perceiving blood glucose in IDDM. Diabetes Care 1985; 8: 529-36
22. Cohen M. Monitoring anticoagulation during percutaneous coronary interventions. J Thromb Thrombolysis 1995; 1: 285-8
23. Seifert R, Borchert W, Letendre P, Knutson R, Cipolle R. Heparin kinetics during hemodialysis: Variation in sensitivity, distribution volume, and dosage. Ther Drug Monit 1986; 8: 32-6
24. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-28S
25. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of un-fractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 782-98
26. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9
27. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for un-fractionated heparin. Arch Intern Med 2001; 161: 385-91
28. Dorman BH, Elliott BM, Spinale FG, et al. Protamine use during peripheral vascular surgery: A prospective randomized trial. J Vasc Surg 1995; 22: 248-55
29. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation 1993; 88: 2728-34
30. Bélisle S. Monitorage de l'héparine durant la circulation extracorporelle. Anticoagulation et réversion. ITBM RBM News 2003; 24: 59S-66S
31. Thompson JF, Mullee MA, Bell PR, et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: A Joint Vascular Research Group study. Eur J Vasc Endovasc Surg 1996; 12: 86-90